What Gensenta İlaç does

Gensenta İlaç Sanayi ve Ticaret A.Ş. is a vertically integrated Turkish pharmaceutical manufacturer producing both finished pharmaceutical products (mamul ilaç) and active pharmaceutical ingredients (APIs). The company operates two principal production complexes: a finished-product facility in Yenibosna, İstanbul, which houses parenteral drug manufacturing (injectable liquid ampoules/vials, lyophilized ampoules/vials, dry powder suspensions), the Onkolitik Üretim Ünitesi (oncology), and the Diğer İlaçlar Üretim Ünitesi (general pharmaceuticals including antibiotics, cardiovascular, corticosteroids, gastrointestinal, multiple sclerosis, and oncology products); and an API facility in Şekerpınar, Kocaeli, with four independent units producing penicillin-group APIs (sulbactam sodium, sultamicillin tosylate/base) and non-penicillin APIs (clarithromycin granules, etodolac, voriconazole). Gensenta holds Turkey's only penicillin production facility, was the first Turkish pharmaceutical manufacturer to obtain FDA approval for finished products (2006), and is described as Turkey's most experienced parenteral drug manufacturer.

The company monetizes through four streams: sale of finished pharmaceutical products (antibiotics, oncology, CNS, cardiovascular, musculoskeletal, and other therapeutic categories) in domestic Turkish and international markets; sale of APIs; international licensing, supply, in-licensing, joint product development, and contract manufacturing arrangements across 28 export countries on 3 continents with 100+ product licenses; and contract manufacturing services. Distribution occurs via Turkish wholesalers and direct healthcare-institution supply domestically, and through partnership / licensing / direct-export models internationally. A Ministry of Science, Industry and Technology-certified R&D Center (since July 19, 2012) supports pharmaceutical development, analytical development, CMC, and scale-up operations.

Gensenta was previously Mustafa Nevzat İlaç (acquired by Amgen İlaç in 2012, renamed Gensenta in 2020), and joined Eczacıbaşı Topluluğu (Eczacıbaşı Group) in November 2022 as a corporate subsidiary. The company employs approximately 600 people, maintains cGMP/cGLP compliance plus ISO 14001, ISO 45001, ISO 50001, EU-GMP (MHRA), German Federal Ministry of Health, and Latvian Health Ministry certifications, and was Turkey's pharmaceutical export champion in 2014 and 2015.

Name

Gensenta İlaç

Legal name

Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi

Website

https://gensenta.com.tr

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Gensenta İlaç is a Turkish vertically integrated pharmaceutical manufacturer producing finished drugs and APIs, including Turkey's only penicillin API facility, exporting to 28 countries, and operating as a subsidiary of Eczacıbaşı Group.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industries

Sterile Injectable Generics (HLAIABAC), Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB), Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP) (HLAGAGAG)

Keywords

• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Finished dosage forms
• Parenteral drug production
• Antibiotic API production

Headquarters

HQ city

Besiktas

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Finished Pharmaceutical Products: Manufacturing and sale of finished pharmaceutical products (mamul ilac) including antibiotics, cardiovascular drugs, gastrointestinal agents, corticosteroids, multiple sclerosis treatments, oncology products, and more. Distributed domestically in Turkey and exported to international markets.
2. Active Pharmaceutical Ingredients (API): Production and sale of pharmaceutical raw materials including penicillin group products (sulbactam sodium, sultamicillin), macrolide antibiotics, and other drug active ingredients (clarithromycin, etodolac, voriconazole).
3. International Licensing and Distribution: License sales and supply partnerships, in-licensing arrangements, and co-product development partnerships with international markets. 100+ licenses across developed and developing countries.
4. Contract Manufacturing: Third-party contract manufacturing services for pharmaceutical products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Gensenta manufactures finished pharmaceutical products (tablets, capsules, injectable ampoules, vials, lyophilized forms, dry powder suspensions) and active pharmaceutical ingredients (APIs) including penicillin derivatives and macrolide antibiotics. The company operates two production facilities—Yenibosna (finished products) and Şekerpınar (APIs)—and supplies both domestic Turkish markets and 28 export countries across three continents through wholesale distribution, licensing, and contract manufacturing.

Product overview

Gensenta İlaç Sanayi ve Ticaret A.Ş. is a vertically integrated pharmaceutical company and one of Turkey's leading finished pharmaceutical products and active pharmaceutical ingredient (API) manufacturers. The company operates two main production facilities: the Yenibosna finished product plant (manufacturing parenteral drugs, oncology products, and other pharmaceuticals) and the Şekerpınar API plant (producing penicillin group APIs, non-penicillin APIs, and pilot-scale products). Gensenta offers finished pharmaceutical products across therapeutic categories including antibiotics, antivirals, dermatologicals, gastrointestinal, hematology, cardiovascular, musculoskeletal, corticosteroids, multiple sclerosis, oncology, and central nervous system medications. The company also provides contract manufacturing and R&D services through its Ministry-certified R&D Center. The product portfolio includes branded finished products (such as Abiratex for oncology, Adeleks for musculoskeletal, Afundas-L for antifungal, Aktibol for vitamin B12, and Alzelon for CNS disorders) and APIs (including penicillin derivatives, macrolides, and various pharmaceutical ingredients).

Differentiator

Problem solved

Functional benefit

Products and services

• Diğer İlaçlar Üretim Ünitesi (Other Pharmaceuticals Manufacturing Unit) Manufacturing facility producing antibiotics (excluding penicillin and cephalosporin groups), corticosteroids, cardiovascular agents, anti-inflammatory agents, gastrointestinal agents, and other therapeutic groups in injectable liquid ampoules, injectable liquid vials, lyophilized ampoules, lyophilized vials, dry powder suspension, tablets, film-coated tablets, and hard gelatin capsules.
• Parenteral İlaç Üretimi (Parenteral Drug Manufacturing) Production of injectable pharmaceutical products including liquid and lyophilized vials, ampoules, and dry powder suspensions at the Yenibosna facility. Turkey's most experienced organization in parenteral drug manufacturing.
• Onkolitik Üretim Ünitesi (Oncology Manufacturing Unit) Specialized facility for the production of liquid and lyophilized vial oncology products.
• Penisilin Grubu Hammadde Üretimi (Penicillin Group API Manufacturing) Active pharmaceutical ingredient production of penicillin group antibiotics including sulbactam sodium, sultamicillin tosylate, and sultamicillin base. Turkey's only penicillin API production facility.
• Penisilin Dışı Hammadde Üretimi (Non-Penicillin API Manufacturing) Production of macrolide group antibiotic APIs and other pharmaceutical ingredients including clarithromycin granules, etodolac, and voriconazole.
• Pilot ve Küçük Ölçekli Üretimler (Pilot and Small-Scale API Production) Pilot and small-scale API production including zoledronic acid, granisetron, rocuronium bromide, aripiprazole, sodium ibandronate monohydrate, and imatinib mesylate.
• Abiratex Abiraterone acetate 250mg tablet used in oncology treatment.
• Adeleks Tiocolchicoside 4mg/2ml IM injection solution in ampoule, also available in 4mg and 8mg tablet forms for musculoskeletal disorders.
• Afundas-L Caspofungin acetate 50mg and 70mg IV lyophilized powder for injection; antifungal medication.
• Aktibol Cobamamide 1000mcg in capsule and lyophilized injection forms; vitamin B12 derivative.
• Alzelon Rivastigmine hydrogen tartrate in 1.5mg, 3mg, 4.5mg, and 6mg capsules for central nervous system disorders.
• Gensenta Ar-Ge Merkezi (R&D Center Services) R&D Center services covering pharmaceutical development, analytical development, CMC, and R&D operations with focus on solid and sterile dosage forms and scale-up studies from laboratory to pilot production.
• Uluslararası Pazarlar (International Licensing & Distribution Services) International business models including sales and distribution partnerships, license sales and supply, in-licensing, joint product development, API sales, and contract manufacturing across 28 countries.

Quantifiable outcome

• Exports to 28 countries across 3 continents
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Eczacıbaşı GroupcoreOthers · 1 November 2022Gensenta became part of Eczacıbaşı Group in November 2022 as one of its corporate group companies. Eczacıbaşı is a major Turkish industrial group with diverse business interests including pharmaceuticals. Gensenta operates as a subsidiary maintaining its brand identity while benefiting from group synergies and shared corporate infrastructure including HR systems, career portals, and sustainability frameworks.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Abdi İbrahim: Turkey's largest domestic pharmaceutical company, manufacturing branded generics, OTC products, and APIs with significant international exports. Directly comparable as a Turkish vertically integrated pharma manufacturer with broad therapeutic portfolio and export focus similar to Gensenta.
• Deva Holding: Turkish pharmaceutical manufacturer producing finished pharmaceuticals, APIs, and sterile injectables with international export operations. Closely comparable to Gensenta as a domestic Turkish peer with API manufacturing, oncology, and sterile injectable capabilities.
• Eczacıbaşı Pharmaceuticals (EIP Eczacıbaşı): Sister company within the Eczacıbaşı Group portfolio producing branded generics and consumer health products. Comparable as a sister pharma manufacturer under the same parent conglomerate, sharing corporate infrastructure and overlapping therapeutic categories.
• Hikma Pharmaceuticals: Jordan-headquartered generic pharmaceutical manufacturer with strong injectable and sterile manufacturing capabilities across US, European, and MENA markets. Comparable to Gensenta as a generic injectable and sterile manufacturer with international regulatory approvals (FDA, EU-GMP) and contract manufacturing services.
• Aurobindo Pharma: Indian vertically integrated pharmaceutical company with major API manufacturing and finished generic dose operations including sterile injectables. Comparable to Gensenta as an API-to-finished-product manufacturer targeting regulated US and European markets with broad therapeutic portfolio.
• Centrient Pharmaceuticals: Netherlands-headquartered specialist manufacturer of beta-lactam antibiotics (penicillins, cephalosporins) and other fermentation-based APIs. Directly comparable to Gensenta's penicillin API production — one of the few Western producers competing in this supply-constrained segment.
• İlko İlaç: Turkish generic pharmaceutical manufacturer producing finished-dose forms (tablets, capsules, injectables) with R&D and contract manufacturing services. Comparable to Gensenta as a domestic Turkish peer in generic finished pharmaceuticals and contract manufacturing.

Broad incumbents

• Sandoz (Novartis): Global leader in generic pharmaceuticals and biosimilars with extensive API and finished-dose manufacturing including sterile injectables. Comparable to Gensenta as a vertically integrated generics and API manufacturer, though operating at significantly larger scale and broader geographic reach.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with broad API, generic, and specialty pharmaceutical portfolio including sterile injectables. Comparable to Gensenta at the category level — generic pharmaceuticals and APIs — but operating at vastly greater scale.
• Viatris: Global generics and biosimilars company formed from Mylan-Upjohn combination, with broad API and finished-dose manufacturing including sterile injectables. Comparable to Gensenta as a vertically integrated generic and API manufacturer with international regulatory certifications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gensentailac
• Instagraminstagram.com/gensentailac
• Xx.com/gensenta_ilac

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gensenta İlaç